Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II study of pembrolizumab plus carboplatin in BRCA-related metastatic breast cancer
2016-001314-25Phase 2Active
- Sponsor
- Azienda Ospedaliera Universitaria Policlinico
- Start
- Dec 2020
- Modality
- DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of pembrolizumab and carboplatin in breast cancer, sponsored by Azienda Ospedaliera Universitaria Policlinico. Primary endpoint: Objective response rate. Started Dec 2020; status: active.
02
Drugs
pembrolizumabcarboplatin
03
Conditions
breast cancer
Beyond the preview
Go deeper on 2016-001314-25.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2016-001314-25.